Hypercholesterolemia, Familial Clinical Trial
— ACHIEVEOfficial title:
A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK0524A 2g Coadministered With Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery Intima Media Thickening (cIMT) in Patients With Heterozygous Familial Hypercholesterolemia (heFH)
Verified date | September 2015 |
Source | Merck Sharp & Dohme Corp. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a 105-week clinical study in patients with heterozygous familial hypercholesterolemia on intensive Low Density Lipoprotein-cholesterol (LDL-C) lowering therapy intended to assess the affects of MK0524A on carotid intima media thickening using ultrasound compared to patients taking placebo. There will be 12 scheduled clinic visits involving review of medical history, physical exam, vital signs, laboratory testing, ultrasound imaging, and electrocardiograms.
Status | Terminated |
Enrollment | 937 |
Est. completion date | August 2008 |
Est. primary completion date | August 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Patients who are 18 to 70 years of age with Heterozygous Familial Hypercholesterolemia and a LDL-C greater than or equal to 100mg/dL and triglycerides less than or equal to 400mg/dL at Visit 1 while on a stable dose of intensive LDL-C lowering therapy Exclusion Criteria: - A condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study - Patients with less than 80% drug study compliance - Patients with chronic medical conditions known to influence serum lipids or lipoproteins or significantly affect the ultrasound acoustic window - Patients with unstable dose of medications - Pregnant or lactating women, or women intending to become pregnant are excluded - Patient with diabetes mellitus that is poorly controlled, or is taking new or recently adjusted antidiabetic pharmacotherapy (with the exception of +/- 10 units of insulin) - Patients with the following conditions: high grade stenosis (greater than 75%) of the carotid artery, chronic heart failure, uncontrolled/unstable cardiac arrhythmias, unstable hypertension, active or chronic hepatobiliary or hepatic disease, HIV positive, episode of gout (within 1 year) |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Merck Sharp & Dohme Corp. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Mean Carotid Intima Media Thickness | change in mean carotid intima media thickness defined as a composite measure of the left and right common, bulb, and internal carotid artery. | after 96 weeks of postrandomization treatment | No |
Secondary | Change in Lipid Profile | after 96 weeks of postrandomization treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04722068 -
Regeneron 1331 Kinetics Sub-Study HoFH
|
N/A | |
Completed |
NCT04118348 -
Evaluating the Efficacy of Pediatric Lipid Screening Alerts
|
N/A | |
Completed |
NCT00000594 -
NHLBI Type II Coronary Intervention Study
|
Phase 3 | |
Completed |
NCT04526457 -
Is Family Screening Improved by Genetic Testing of Familial Hypercholesterolemia
|
N/A | |
Completed |
NCT01753232 -
Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter
|
N/A | |
Completed |
NCT03018678 -
Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia
|
||
Completed |
NCT00134485 -
Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia
|
Phase 3 | |
Completed |
NCT00134511 -
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
|
Phase 3 | |
Recruiting |
NCT04073797 -
PET Imaging of Inflammation and Lipid Lowering Study
|
N/A | |
Terminated |
NCT01583647 -
A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
|
Phase 1 | |
Completed |
NCT00515307 -
Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia
|
Phase 1 | |
Recruiting |
NCT04656028 -
Genetic Testing and Motivational Counseling for FH
|
N/A | |
Terminated |
NCT00092833 -
Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)
|
Phase 3 | |
Active, not recruiting |
NCT04837638 -
Diet Quality and Coronary Artery Calcification in Adults With Heterozygous Familial Hypercholesterolemia
|
||
Completed |
NCT00280995 -
Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy
|
Phase 2 | |
Completed |
NCT06231459 -
Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia
|
Phase 4 | |
Completed |
NCT01524289 -
Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)
|
Phase 3 | |
Completed |
NCT00281008 -
Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy
|
Phase 2 | |
Recruiting |
NCT03989167 -
Clinical Decision Support for Familial Hypercholesterolemia
|
N/A | |
Completed |
NCT03795038 -
Comparison of the Plasma Lipoprotein Apheresis Systems DIAMED and MONET vs. the Whole Blood Apheresis System DALI
|
N/A |